{"nctId":"NCT02480712","briefTitle":"Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection","startDateStruct":{"date":"2015-07-01","type":"ACTUAL"},"conditions":["Hepatitis C Virus Infection"],"count":107,"armGroups":[{"label":"SOF/VEL","type":"EXPERIMENTAL","interventionNames":["Drug: SOF/VEL"]}],"interventions":[{"name":"SOF/VEL","otherNames":["GS-7977/GS-5816","Epclusa®"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* HCV RNA ≥ 10\\^4 IU/mL at screening\n* HCV genotype 1, 2, 3, 4, 5, 6\n* Cirrhosis determination, a fibroscan or liver biopsy may be required\n* HIV-1 infection\n* Use of protocol specified method(s) of contraception\n* Screening laboratory values within defined thresholds\n\nKey Exclusion Criteria:\n\n* Clinically-significant illness (other than HCV or HIV) or any other major medical disorder that may interfere with individual's treatment, assessment or compliance with the protocol\n* Current or prior history of clinical hepatic decompensation, hepatocellular carcinoma (HCC) or other malignancy (with the exception of certain resolved skin cancers)\n* Screening ECG with clinically significant abnormalities\n* Pregnant or nursing female or male with pregnant female partner\n* Infection with hepatitis B virus (HBV)\n* Use of any prohibited concomitant medications as described in the protocol\n* Chronic use of systemically administered immunosuppressive agents\n\nNOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)","description":"SVR4 and SVR24 were defined as HCV RNA \\< LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ on Treatment","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"HCV RNA Change From Baseline/Day 1","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.47","spread":"0.606"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.97","spread":"0.577"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.15","spread":"0.560"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.18","spread":"0.572"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.17","spread":"0.575"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.17","spread":"0.575"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.17","spread":"0.575"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Virologic Failure","description":"Virologic failure was defined as:\n\n* On-treatment virologic failure:\n\n  * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ while on treatment), or\n  * Rebound (confirmed \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or\n  * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)\n* Virologic relapse:\n\n  * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at last on-treatment visit","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants That Maintained HIV-1 RNA < 50 Copies/mL While On HCV Treatment","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.4","spread":null},{"groupId":"OG001","value":"97.1","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.3","spread":null},{"groupId":"OG001","value":"97.1","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.2","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"92.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Creatinine Change From Baseline At the End of Treatment and At Posttreatment Week 12","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.196"},{"groupId":"OG001","value":"0.04","spread":"0.107"},{"groupId":"OG002","value":"0.00","spread":"0.083"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.153"},{"groupId":"OG001","value":"0.02","spread":"0.142"},{"groupId":"OG002","value":"-0.06","spread":"0.204"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":56},"commonTop":["Fatigue","Headache","Upper respiratory tract infection","Diarrhoea","Arthralgia"]}}}